PeptideCompareBromantane (Ladasten) — EU research guide.
Bromantane is a synthetic adamantane derivative developed in Russia as an 'actoprotector' and reported to be marketed there as Ladasten. Human data are limited and mostly Russian, and it is on the WADA Prohibited List.
What is Bromantane (Ladasten)?
Bromantane (N-(2-adamantyl)-N-(4-bromophenyl)amine) is a synthetic adamantane derivative developed in Russia in the late Soviet period as an 'actoprotector', a class of substances meant to raise physical and mental performance under stress. It is reported to be marketed in Russia as Ladasten for neurasthenia (asthenia). The proposed mechanism is indirect dopaminergic and serotonergic activity: an animal paper describes increased tyrosine hydroxylase expression and dopamine in the nucleus accumbens, plus some serotonin reuptake inhibition at certain concentrations. Human pharmacology is poorly characterised in English-language sources. The CAS number and molecular weight shown are taken from secondary sources and were not confirmed in a chemical registry.
What does the research show?
Human data are limited and come almost entirely from Russian groups. A small pilot study and a placebo-controlled study in neurasthenia (Neznamov et al., 2009) exist, but their results could not be verified for this guide, so no trial numbers are given. Secondary sources describe a larger multicentre study in asthenia with mostly mild adverse events; this was not checked against a primary source. Most of the remaining literature is Russian animal work on acute and chronic toxicity, reproductive and offspring development in rats, and behavioural and cardiovascular effects. No independent Western clinical trials were found, and no verified human half-life is available. An English review of actoprotectors (Oliynyk and Oh, 2012) is the easiest overview.
EU legal status
No EU marketing authorisation for bromantane was found, but this was not checked against every national register and no EMA source page was located, so the status is unverified. In Russia it is reported, by secondary sources only, to have been approved as Ladasten around 2009 for neurasthenia. Bromantane is named on the WADA Prohibited List under S6.A (non-specified stimulants). Whether the S6 prohibition applies in competition only was not re-checked. A vendor research vial is not the licensed Russian medicine.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Bromantane (Ladasten) across EU suppliers
COA-verified EU vendors · Updated monthly
References
- Placebo-controlled Russian study of Ladasten in neurasthenia; the citation is confirmed, but the abstract and results were not read, so no efficacy numbers are quoted. Neznamov GG, Siuniakov SA, Teleshova ES, Chumakov DV. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo). Zh Nevrol Psikhiatr Im S S Korsakova 2009;109(5):20-26. Source
- English-language overview of actoprotectors, including bromantane. Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul) 2012. PubMed 24009833Source
- Early Russian pharmacology paper on bromantane; the content was not read. Seredenin SB, Miramedova AG. Analysis of pharmacological properties of bromantane. Biull Eksp Biol Med 1999. PubMed 10640239Source
- Animal developmental toxicity work (offspring maturation and reflexes); the results were not read. Iezhitsa IN, Spasov AA, Bugaeva LI. Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicol Teratol 2001. PubMed 11348840Source